Literature DB >> 20631150

Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors.

Denis M Tebit1, Michael Lobritz, Matthew Lalonde, Taina Immonen, Kamlendra Singh, Stefanos Sarafianos, Ottmar Herchenröder, Hans-Georg Kräusslich, Eric J Arts.   

Abstract

Natural evolution in primate lentiviral reverse transcriptase (RT) appears to have been constrained by the necessity to maintain function within an asymmetric protein composed of two identical primary amino acid sequences (66 kDa), of which one is cleaved (51 kDa). In this study, a detailed phylogenetic analysis now segregates groups O and M into clusters based on a cysteine or tyrosine residue located at position 181 of RT and linked to other signature residues. Divergent evolution of two group O (C181 or Y181) and the main (Y181 only) HIV-1 lineages did not appreciably impact RT activity or function. Group O RT structural models, based on group M subtype B RT crystal structures, revealed that most evolutionarily linked amino acids appear on a surface-exposed region of one subunit while in a noncatalytic RT pocket of the other subunit. This pocket binds nonnucleoside RT inhibitors (NNRTI); therefore, NNRTI sensitivity was used to probe enzyme differences in these group O and M lineages. In contrast to observations showing acquired drug resistance associated with fitness loss, the C181Y mutation in the C181 group O lineage resulted in a loss of intrinsic NNRTI resistance and was accompanied by fitness loss. Other mutations linked to the NNRTI-resistant C181 lineage also resulted in altered NNRTI sensitivity and a net fitness cost. Based on RT asymmetry and conservation of the intricate reverse transcription process, millions of years of divergent primate lentivirus evolution may be constrained to discrete mutations that appear primarily in the nonfunctional, solvent-accessible NNRTI binding pocket.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20631150      PMCID: PMC2937803          DOI: 10.1128/JVI.00991-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Human immunodeficiency virus. Phylogeny and the origin of HIV-1.

Authors:  A Rambaut; D L Robertson; O G Pybus; M Peeters; E C Holmes
Journal:  Nature       Date:  2001-04-26       Impact factor: 49.962

2.  Origins and evolution of AIDS viruses: estimating the time-scale.

Authors:  P M Sharp; E Bailes; F Gao; B E Beer; V M Hirsch; B H Hahn
Journal:  Biochem Soc Trans       Date:  2000-02       Impact factor: 5.407

3.  Timing the ancestor of the HIV-1 pandemic strains.

Authors:  B Korber; M Muldoon; J Theiler; F Gao; R Gupta; A Lapedes; B H Hahn; S Wolinsky; T Bhattacharya
Journal:  Science       Date:  2000-06-09       Impact factor: 47.728

4.  Functional characterization of chimeric reverse transcriptases with polypeptide subunits of highly divergent HIV-1 group M and O strains.

Authors:  L Menéndez-Arias; A Abraha; M E Quiñones-Mateu; A Mas; M J Camarasa; E J Arts
Journal:  J Biol Chem       Date:  2001-05-15       Impact factor: 5.157

5.  A new human immunodeficiency virus derived from gorillas.

Authors:  Jean-Christophe Plantier; Marie Leoz; Jonathan E Dickerson; Fabienne De Oliveira; François Cordonnier; Véronique Lemée; Florence Damond; David L Robertson; François Simon
Journal:  Nat Med       Date:  2009-08-02       Impact factor: 53.440

6.  Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs.

Authors:  V S Torre; A J Marozsan; J L Albright; K R Collins; O Hartley; R E Offord; M E Quiñones-Mateu; E J Arts
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

7.  Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture.

Authors:  R H Archer; C Dykes; P Gerondelis; A Lloyd; P Fay; R C Reichman; R A Bambara; L M Demeter
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

8.  A transitional endogenous lentivirus from the genome of a basal primate and implications for lentivirus evolution.

Authors:  Robert J Gifford; Aris Katzourakis; Michael Tristem; Oliver G Pybus; Mark Winters; Robert W Shafer
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

9.  Origin and biology of simian immunodeficiency virus in wild-living western gorillas.

Authors:  Jun Takehisa; Matthias H Kraus; Ahidjo Ayouba; Elizabeth Bailes; Fran Van Heuverswyn; Julie M Decker; Yingying Li; Rebecca S Rudicell; Gerald H Learn; Cecile Neel; Eitel Mpoudi Ngole; George M Shaw; Martine Peeters; Paul M Sharp; Beatrice H Hahn
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

10.  HIV-1 group O infection in Cameroon, 1986 to 1998.

Authors:  A Ayouba; P Mauclère; P M Martin; P Cunin; J Mfoupouendoun; B Njinku; S Souquières; F Simon
Journal:  Emerg Infect Dis       Date:  2001 May-Jun       Impact factor: 6.883

View more
  16 in total

1.  HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs.

Authors:  Denis M Tebit; Hamish Patel; Annette Ratcliff; Elodie Alessandri; Joseph Liu; Crystal Carpenter; Jean-Christophe Plantier; Eric J Arts
Journal:  AIDS Res Hum Retroviruses       Date:  2016-03-16       Impact factor: 2.205

2.  HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120.

Authors:  Annette N Ratcliff; Wuxian Shi; Eric J Arts
Journal:  J Virol       Date:  2012-11-07       Impact factor: 5.103

3.  Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc.

Authors:  Michael A Lobritz; Annette N Ratcliff; Andre J Marozsan; Dawn M Dudley; John C Tilton; Eric J Arts
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

4.  Effect of natural polymorphisms in the HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibility.

Authors:  André F A Santos; Denis M Tebit; Matthew S Lalonde; Ana B Abecasis; Annette Ratcliff; Ricardo J Camacho; Ricardo S Diaz; Ottmar Herchenröder; Marcelo A Soares; Eric J Arts
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

Review 5.  HIV-1 antiretroviral drug therapy.

Authors:  Eric J Arts; Daria J Hazuda
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

6.  Long-term control of viral replication in a Group O, human immunodeficiency virus type 1-infected individual.

Authors:  Robert W Buckheit; Stephen B Sexauer; Ahmad R Sedaghat; Claus O Wilke; Oliver Laeyendecker; Christie R Basseth; Joel N Blankson
Journal:  AIDS Res Hum Retroviruses       Date:  2014-06       Impact factor: 2.205

7.  In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.

Authors:  Steffen Wildum; Daniela Paulsen; Kai Thede; Helga Ruebsamen-Schaeff; Holger Zimmermann
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

8.  Commentary on the role of treatment-related HIV compensatory mutations on increasing virulence: new discoveries twenty years since the clinical testing of protease inhibitors to block HIV-1 replication.

Authors:  Eric J Arts
Journal:  BMC Med       Date:  2012-10-03       Impact factor: 8.775

9.  Effect of intercalator and Lewis acid-base branched peptide complex formation: boosting affinity towards HIV-1 RRE RNA.

Authors:  Jessica E Wynn; Wenyu Zhang; Denis M Tebit; Laurie R Gray; Marie-Louise Hammarskjold; David Rekosh; Webster L Santos
Journal:  Medchemcomm       Date:  2016-06-06       Impact factor: 3.597

10.  Characterization and in vitro activity of a branched peptide boronic acid that interacts with HIV-1 RRE RNA.

Authors:  Jessica E Wynn; Wenyu Zhang; Denis M Tebit; Laurie R Gray; Marie-Louise Hammarskjold; David Rekosh; Webster L Santos
Journal:  Bioorg Med Chem       Date:  2016-04-05       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.